Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases
نویسندگان
چکیده
منابع مشابه
Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndrome.
A 44-year-old woman was found to have elevated aminotransferases, twice the upper limit of normal. Liver biopsy demonstrated a mixed inflammatory process suggestive of both primary biliary cirrhosis and autoimmune hepatitis (AIH). Prednisone and azathioprine were started, with normalization of aminotransferases. Six months later, she returned with worsening pruritus and re-evaluation demonstrat...
متن کاملSuccessful use of rituximab in Evans syndrome and refractory immune thrombocytopenic purpura.
Immune cytopenias are mediated by auto-antibodies produced by B-lymphocytes. Conventional treatment of immune-mediated haematological disorders includes immunosuppression with steroids and other immune modulating therapies and in some refractory cases, splenectomy. Response rates to conventional and second-line agents are variable and a proportion of patients require lifelong immunosuppression ...
متن کاملRituximab therapy for childhood Evans syndrome.
The safety and efficacy of rituximab have been retrospectively assessed in 17 children with Evans syndrome. Patients received 4 or 3 weekly doses of rituximab (375 mg/m(2) per dose) associated with prednisone, alone (14 patients) or associated with other immunosuppressive drugs. Complete or partial remission of at least one cytopenia was achieved in 13 out of the 17 patients (76%), and lasted i...
متن کاملRituximab therapy in pemphigus and other autoantibody-mediated diseases
Rituximab, a monoclonal antibody targeting the B cell marker CD20, was initially approved in 1997 by the United States Food and Drug Administration (FDA) for the treatment of non-Hodgkin lymphoma. Since that time, rituximab has been FDA-approved for rheumatoid arthritis and vasculitides, such as granulomatosis with polyangiitis and microscopic polyangiitis. Additionally, rituximab has been used...
متن کاملHyperactive cellular immune responses produce autoimmune and other immune-mediated diseases while hypoactive cell-mediated immunity
Immune competence is provided and maintained by two cellular systems which involve lymphocytes, produced by the body's primary (bone marrow and thymus) and secondary (lymph nodes and spleen) lymphatic organs. They are descendants of the bone marrow's pool of stem cells, and constitute a circulating or humoral immune system derived from B-cells (bursa-dependent or bone marrow derived), and a cel...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Hematology
سال: 2004
ISSN: 0361-8609,1096-8652
DOI: 10.1002/ajh.20180